调强放疗与化疗联合重组人P53腺病毒注射液治疗IIb期-IIIb期宫颈鳞癌的临床疗效  

Clinical efficacy of intensity modulated radiotherapy combined with chemotherapy combined with recombinant human P53 adenovirus injection in the treatment of stage IIb to IIIb cervical squamous cell carcinoma

作　　者：崔琳 杨林[2] Lin CUI;Lin YANG(Anhui Medical University, Hefei 230000, China;Department of Radiotherapy, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China)

机构地区：[1]安徽医科大学,安徽合肥230000 [2]安徽医科大学第一附属医院放疗科,安徽合肥230022

出　　处：《临床检验杂志（电子版）》2017年第2期173-175,共3页Clinical Laboratory Journal(Electronic Edition)

摘　　要：目的分析调强放疗与化疗联合重组人P53腺病毒注射液治疗IIb期-IIIb期宫颈鳞癌的临床效果。方法选取IIb期-IIIb期宫颈鳞癌的患者47例,随机分为观察组和对照组,观察组给予瘤体内注射重组人P53腺病毒注射液1×10^(12)-2×10^(12) VP,72 h后给放疗与化疗,自放疗第1天,每隔7 d给予顺铂40 mg/m^2静脉滴注。对照组除了不给予重组人P53腺病毒注射液治疗,其他处理同观察组。治疗结束8周后评价肿瘤的近期疗效,并定量分析两组放疗前后DNA倍体指数的变化。结果近期控制率中,观察组24例患者,完全缓解(CR)15例(62.5%);部分缓解(PR)7例(29.1%);有效率为91.6%;对照组23例,CR 9例(39.1%);PR 8例(34.8%);有效率为73.9%;观察组治疗有效率明显优于对照组,差异有统计学意义(P<0.05)。两组患者治疗后行DNA倍体定量分析,观察组与对照组比较差异有统计学意义(P<0.05)。结论调强放疗与化疗联合重组人P53腺病毒注射液在治疗局部中晚期宫颈鳞癌有着较为显著的临床效果,远期疗效仍需进一步研究。Objective To analyze the clinical efficacy of intensity modulated radiotherapy and chemotherapy combinedwith recombinant human P53adenovirus injection in the treatment of cervical squamous cell carcinoma of stage IIb toIIIb.Methods A total of47patients with stage IIb to IIIb cervical squamous cell carcinoma were randomly divided into observationgroup and control group.Patients in the observation group were given intratumoral injection of recombinant adenovirusP53injection1×1012-2×1012VP,72h for intensity-modulated radiotherapy and chemotherapy,since the frist day,cisplatin40mg/m2intravenous drip was given every7days.Patients in the control group were not treated with recombinant human P53adenovirus injection,but the other treatment was the same as the observation group.At the end of8weeks after treatment,therecent curative effect was evaluated,and quantitative analysis of the change of DNA ploidy index before and after radiotherapyin two groups were compared.Results The recent rate of24cases in the observation group,15cases(62.5%)with completeresponse(CR);7cases(29.1%)with partial response(PR);the response rate was91.6%.The recent rate of23cases in the controlgroup,9cases(39.1%)with CR;8cases(34.8%)with PR;the response rate was73.9%.The effective rate of the observation groupwas obviously better than that of the control group,the difference was statistically significant(P<0.05).After treatment,twogroups of patients were received DNA ploidy quantitative analysis,and the difference between the two groups was statisticallysignificant(P<0.05).Conclusions Intensity modulated radiation therapy and chemotherapy with recombinant human P53adenovirusinjection has significant clinical effect in the treatment of locally advanced squamous cell carcinoma of the cervix.Thelong-term effect needs to be further studied.

关 键 词：调强放疗 同步化疗 重组人P53腺病毒注射液 

分 类 号：R737.33[医药卫生—肿瘤]